» Articles » PMID: 31935687

FHL3 Promotes Pancreatic Cancer Invasion and Metastasis Through Preventing the Ubiquitination Degradation of EMT Associated Transcription Factors

Overview
Specialty Geriatrics
Date 2020 Jan 15
PMID 31935687
Citations 18
Authors
Affiliations
Soon will be listed here.
Abstract

Pancreatic ductal adenocarcinoma (PDAC) is intractable due to its strong invasiveness and metastatic ability. Epithelial-mesenchymal transition (EMT) is the pivotal driver of tumor invasion and metastasis. The four-and-a-half LIM domain (FHL) family is involved in regulating transforming growth factor (TGF)-β and Ras signaling, which might control the EMT process. In this study, we found that higher expression of four-and-a-half LIM domains 3 (FHL3) predicted poor prognosis in PDAC. The decreasing of FHL3 changed the EMT phenotype by blocking the TGFβ/Atk/GSK3β/ubiquitin pathways. Interestingly, the GSK3β inhibitor could abrogate the role of FHL3 in the regulation of snail1 and twist1 expression, which implied that GSK3β plays a pivotal role in the FHL3-mediated EMT process. Furthermore, we found that FHL3 can directly bind to GSK3β, which weakened the interaction between GSK3β and snail1/twist1. We also found that the LIM-3 domain of FHL3 was required for the binding of FHL3 to GSK3β. Collectively, our study implied that FHL3, as a binding partner of GSK3β, promoted tumor metastasis in PDAC through inhibiting the ubiquitin-degradation of snail1 and twist1.

Citing Articles

Construction of an anaplastic thyroid cancer stratification signature to guide immune therapy selection and validation of the pivotal gene HLF through experiments.

Pengping L, Kexin Y, Yuwei X, Ke S, Rongguo L, Zhenyu W Front Immunol. 2025; 15:1478904.

PMID: 39872516 PMC: 11769983. DOI: 10.3389/fimmu.2024.1478904.


Emerging horizons on molecular and circulating biomarkers in pancreatic adenocarcinoma.

Moretti M, Farina A, Angeloni A, Anastasi E Front Oncol. 2024; 14:1483306.

PMID: 39575418 PMC: 11578827. DOI: 10.3389/fonc.2024.1483306.


Identification and clinical validation of diverse cell-death patterns-associated prognostic features among low-grade gliomas.

Yang W, Yu H, Lei Q, Pu C, Guo Y, Lin L Sci Rep. 2024; 14(1):11874.

PMID: 38789729 PMC: 11126566. DOI: 10.1038/s41598-024-62869-4.


Overexpression of FHL1 suppresses papillary thyroid cancer proliferation and progression via inhibiting Wnt/β-catenin pathway.

Chen J, Zeng C, Jin J, Zhang P, Zhang Y, Zhang H Endocrine. 2024; 85(1):238-249.

PMID: 38191984 DOI: 10.1007/s12020-023-03675-2.


TJP3 promotes T cell immunity escape and chemoresistance in breast cancer: a comprehensive analysis of anoikis-based prognosis prediction and drug sensitivity stratification.

Chaojun L, Pengping L, Yanjun L, Fangyuan Z, Yaning H, Yingbo S Aging (Albany NY). 2023; 15(22):12890-12906.

PMID: 37950731 PMC: 10713417. DOI: 10.18632/aging.205208.


References
1.
Moore M, Goldstein D, Hamm J, Figer A, Hecht J, Gallinger S . Erlotinib plus gemcitabine compared with gemcitabine alone in patients with advanced pancreatic cancer: a phase III trial of the National Cancer Institute of Canada Clinical Trials Group. J Clin Oncol. 2007; 25(15):1960-6. DOI: 10.1200/JCO.2006.07.9525. View

2.
Coghill I, Brown S, Cottle D, McGrath M, Robinson P, Nandurkar H . FHL3 is an actin-binding protein that regulates alpha-actinin-mediated actin bundling: FHL3 localizes to actin stress fibers and enhances cell spreading and stress fiber disassembly. J Biol Chem. 2003; 278(26):24139-52. DOI: 10.1074/jbc.M213259200. View

3.
Lee J, Jung S, Yang K, Bae E, Ahn S, Park J . A20 promotes metastasis of aggressive basal-like breast cancers through multi-monoubiquitylation of Snail1. Nat Cell Biol. 2017; 19(10):1260-1273. DOI: 10.1038/ncb3609. View

4.
Zeisberg M, Neilson E . Biomarkers for epithelial-mesenchymal transitions. J Clin Invest. 2009; 119(6):1429-37. PMC: 2689132. DOI: 10.1172/JCI36183. View

5.
Sala S, Ampe C . An emerging link between LIM domain proteins and nuclear receptors. Cell Mol Life Sci. 2018; 75(11):1959-1971. PMC: 11105726. DOI: 10.1007/s00018-018-2774-3. View